Lilly launches Mounjaro pen in India at $160 for starting dose, stepping up Novo rivalry
(Reuters) -Eli Lilly on Wednesday launched the easy-to-use injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees (nearly $160) for its starting dose of 2.5 mg in India, stepping up competition with Novo Nordisk.
Lilly said in June it received approval from India's drug regulator for its once-weekly Mounjaro Kwikpen, two days after Novo Nordisk launched Wegovy in multiple dose strengths in a similar pen device.
Mounjaro Kwikpen is available in six dose strengths — 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg — with pricing calculated for a month's supply.
The smallest two doses are priced at 14,000 and 17,500 rupees, respectively, and the 7.5 mg and 10 mg doses cost 22,000 rupees. The 12.5 mg and 15 mg doses cost 27,500 rupees, the company said.
"If we look at how the highest doses of Mounjaro and Wegovy are priced, it appears (that) Mounjaro's pricing is attractive and competitive," said Vishal Manchanda from Systematix Institutional Equities.
Wegovy's smallest doses of 0.25 mg, 0.5 mg and 1 mg cost 17,345 rupees a month, and its highest doses of 1.7 mg and 2.4 mg cost 24,280 rupees and 26,015 rupees a month, respectively.
Lilly began selling Mounjaro in India in late March for diabetes and obesity in 2.5 mg and 5 mg vials. Both drugs have seen strong demand since then, with sales in July doubling month-on-month.
The drugs belong to a class of therapies known as GLP-1 receptor agonists that help control blood sugar and slow digestion, making people feel fuller for longer.
($1 = 87.6650 Indian rupees)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Jim Cramer on Eli Lilly Stock: 'It Just Got Pole-Axed, Laid to Waste'
Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer commented on. Cramer highlighted the reasons behind the stock's decline recently. He remarked: 'Last and least, I look at the drug stocks and I can't believe how awful they really are, with now Eli Lilly last joining the ugly fray with its less than impactful, less thought weight loss, the pill. The Street was hoping that Lilly would be able to replace its onerous GLP-1 injection with a simple pill that would produce an equal amount of weight loss. No such luck. The stock, it just got pole-axed, laid to waste.' Pixabay/Public Domain Eli Lilly and Company (NYSE:LLY) develops and markets pharmaceuticals for diabetes, obesity, cancer, autoimmune conditions, neurological disorders, and other diseases. The company's portfolio includes treatments across multiple therapeutic areas. In a July episode, Cramer mentioned the company and said: 'What I'm thinking, as someone who owns Eli Lilly for the Charitable Trust and who wishes I owned PepsiCo, is that there might be a short-term peak in the use of these drugs (GLP-1s). The Achilles heel of these drugs is that they're too effective. At some point, you lose enough weight, and you might think you can stop taking them… Whatever the case, if Eli Lilly is going to break out from this level, it needs breakthroughs in new areas, heart, brain, that it just doesn't have right now, or there has to be some new data that shows something else positive that the GLP-1 drugs can do. While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Shilpa Medicare's NorUDCA Makes History as First Approved NAFLD Therapy Worldwide
Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a billion people affected by Non-Alcoholic Fatty Liver Disease (NAFLD) NAFLD affects 1 in 4 people globally (1.2 billion), with 188 million patients in India—most undiagnosed until irreversible damage occurs. A Breakthrough in Liver Health: NorUDCA delivers a novel dual-action mechanism, combining anti-inflammatory benefits with enhanced bile acid regulation. This innovative therapy promises to halt the progression of NAFLD to severe liver conditions such as NASH, cirrhosis, and liver failure. Clinically Proven and Safe: Robust clinical trials demonstrate NorUDCA's significant superiority over placebo in efficacy, with an excellent safety profile and no major adverse events reported RAICHUR, India, Aug. 14, 2025 /PRNewswire/ -- In a landmark moment for global hepatology and Indian pharmaceutical innovation, Shilpa Medicare Limited (BSE: 530661) (NSE: SHILPAMED) has secured the world's first regulatory approval from India's Central Drugs Standard Control Organization (CDSCO) for Nor Ursodeoxycholic Acid (NorUDCA) Tablets 500 mg, the first-ever approved therapy targeting NAFLD. Mr. Vishnukant Bhutada, Managing Director, Shilpa Medicare, hailed the approval as a "transformational leap": "Receiving approval for NorUDCA marks a transformational leap—not only for Shilpa Medicare but for millions silently suffering from liver disease. We are honored to be the first company globally to bring this innovative therapy to patients, reflecting our unwavering commitment to pioneering healthcare solutions and expanding access to life-changing treatments across India and beyond. We are excited to launch NorUDCA in India immediately and are actively pursuing approvals worldwide to ensure this vital therapy reaches patients everywhere in need." Shilpa Medicare is committed to rapidly commercializing NorUDCA in India and pursuing international regulatory pathways, aiming to bring this life-altering treatment to patients on a global scale About Shilpa Medicare Limited: Shilpa Medicare Limited is a fully integrated pharmaceutical group specializing in innovative Oncology and Non-Oncology APIs, Peptides, Polymers, New Biological Entities and differentiated finished dosage formulations such as Orally Dispersible Films and Transdermal Patches. The company offers end-to-end CDMO services to global pharmaceutical partners, supported by four advanced R&D centers and seven manufacturing facilities, consistently driving innovation and quality in healthcare. View original content: SOURCE Shilpa Medicare Limited
Yahoo
6 hours ago
- Yahoo
1 Reason to Buy Eli Lilly (LLY) Stock
Key Points Eli Lilly specializes in obesity and diabetes treatments, among other areas. It's reasonable to expect a lot more growth from the company. Its shares aren't exactly cheap at recent levels, though. 10 stocks we like better than Eli Lilly › Shares of Eli Lilly (NYSE: LLY) have made some investors much richer. Over the last decade, for example, Eli Lilly stock averaged annual gains of 25.1%, enough to turn a $10,000 investment into a stake worth $94,204. (The S&P 500 index averaged a still-respectable 12.7% over the same period, turning $10,000 into $33,117.) Had you reinvested your Lilly dividends into more shares of stock along the way, your average gain would have been 26.9%, and your investment's value $108,082. If you're not an Eli Lilly shareholder, you might be wondering whether you should become one. Well, there's certainly a solid green flag or two. Unfortunately, there's a red flag, too. A key reason to buy into Eli Lilly is its solid portfolio of drugs and drugs in development. It's already a leader in the increasingly popular realm of weight loss drugs -- with weight loss drug Zepbound and diabetes drug Mounjaro -- and its cancer drug Verzenio is very promising, too. And those are just some of its drugs. My colleague Keith Speights has suggested that Lilly might become the first healthcare company to cross the $1 trillion mark in market value. Of course, not every drug will become a best-seller -- and some never even get approved. Eli Lilly reported some disappointing results for its weight loss drug orforglipron recently, which sent its shares downward -- even though patients taking it did lose significant weight. So what's the red flag? Well, it's Eli Lilly's valuation. With a recent price-to-earnings (P/E) ratio of 61, well above its five-year average of 50, the stock seems a bit richly priced -- though not wildly overpriced. You could still load up on it if you're a long-term investor, or you could buy into the stock gradually over time. Note, too, that President Trump's threatened tariffs could hurt pharmaceutical companies in general. Do the experts think Eli Lilly is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Eli Lilly make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,060% vs. just 182% for the S&P — that is beating the market by 877.59%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 Selena Maranjian has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. 1 Reason to Buy Eli Lilly (LLY) Stock was originally published by The Motley Fool Sign in to access your portfolio
